Table 4. Monoclonal subtype for L. pneumophila serogroup 1 isolates, European Union–European Economic Area, 2008−2017.
| Monoclonal subtype | Community-acquired cases, no. (%) | Healthcare-associated cases, no. (%) |
|---|---|---|
| Monoclonal antibody 3/1–positive* | ||
| Allentown | 4 (0.5) | 1 (1.1) |
| Allentown/France | 198 (25.8) | 8 (8.9) |
| Benidorm | 105 (13.7) | 9 (10.0) |
| France | 1 (0.1) | 0 |
| Knoxville | 197 (25.7) | 5 (5.6) |
| Philadelphia | 135 (17.6) | 16 (17.8) |
| Subtotal |
640 (83.6) |
39 (43.3) |
| Monoclonal antibody 3/1–negative | ||
| Bellingham | 38 (5.0) | 11 (12.2) |
| Camperdown | 4 (0.5) | 0 |
| Heysham | 0 | 1 (1.1) |
| OLDA | 26 (3.4) | 15 (16.7) |
| Oxford | 3 (0.4) | 1 (1.1) |
| Oxford/OLDA | 55 (7.2) | 23 (25.6) |
| Subtotal |
126 (16.4) |
51 (56.7) |
| Total | 766 (100.0) | 90 (100.0) |
*Monoclonal types are grouped by the presence (or lack) of the virulence-associated epitope recognized by the monoclonal antibody 3/1 (Dresden Panel) (10).